DOCSLIB.ORG

Budesonide (UCERIS) Rectal Foam National Drug Monograph March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Budesonide (UCERIS) Rectal Foam National Drug Monograph March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives Budesonide (UCERIS) Rectal Foam National Drug Monograph March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Budesonide is a potent, non-halogenated, synthetic glucocorticoid with weak Action mineralocorticoid activity. Prevents or controls inflammation. Indication(s) Under Review in Induction of remission in patients with active mild to moderate distal ulcerative This Document colitis extending up to 40 cm from the anal verge. Dosage Form(s) Under Rectal foam, 2 mg per actuation / metered dose, aerosolized. Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category C Executive Summary Efficacy budesonide foam had a small, statistically significant benefit over placebo in inducing remission and resolving rectal bleeding, and produced improvement in rectal bleeding as early as Week 1 Budesonide foam and hydrocortisone acetate foam were similar in remission efficacy and in safety in patients with ulcerative proctitis or proctosigmoiditis. twice daily dosing of budesonide foam was shown to be superior to once daily dosing in terms of mucosal healing. Safety Budesonide foam was not shown to have a lower risk of glucocorticoid-related adverse events than hydrocortisone foam enema. Mean morning cortisol concentrations remained within normal limits throughout therapy with budesonide foam, although cortisol concentrations decreased during twice daily dosing in weeks 1 and 2 then returned to baseline by week 4. There was a low incidence of clinically relevant effects on adrenal suppression. The effect of CYP3A4 inhibitors and inducers on the pharmacokinetics of budesonide administered as rectal foam has not been studied. Other Considerations The small volume (25 ml) of each dose of budesonide foam was intended to minimize retention effort, improve distribution to the rectum and sigmoid colon and improve patient comfort relative to conventional liquid enemas and suppositories. One trial, which compared budesonide (BUDENOFALK) foam with budesonide suspension (ENTOCORT) enema, supports the proposal that budesonide (UCERIS) foam reduces retention problems and is preferred by more patients than the suspension enema. The prescribing information for budesonide foam does not make any recommendations about tapering the dose upon discontinuation of therapy. Projected Place in Considering relative drug acquisition costs and similar efficacy and safety, Therapy budesonide foam may be reserved for patients with ulcerative proctitis or proctosigmoiditis / distal UC who have an inadequate response or intolerance to hydrocortisone rectal foam. Since budesonide foam comes in metered-dose aerosolized canisters, it may be considered in patients who, despite repeated patient education, continue to have problems manually measuring or dispensing doses of hydrocortisone foam. Budesonide Rectal Foam Monograph Rectal glucocorticoid therapy is recommended as second-line treatment after rectal 5-ASA therapies and may be used concomitantly with systemic therapies for additional benefit. Background Purpose for Review Budesonide (UCERIS) extended release tablets were reviewed in March and July 2015 (nonformulary with criteria for use). The rectal foam is a new formulation that has an indication different from the extended-release tablets. Issues to be determined: Evidence of need Does budesonide rectal foam offer efficacy or safety advantages over currently available formulary and nonformulary alternatives? Are there patient subgroups that have greater efficacy or safety effects? Does budesonide rectal foam have specific characteristics best managed by the nonformulary process, prior authorization, or criteria for use? Other Therapeutic Formulary Alternatives Options (Rectal Products) Other Considerations Clinical Guidance Hydrocortisone Enema1 100 mg / 60 ml solution in Approved for adjunctive single-dose bottles with treatment of UC lubricated applicator tips. Dosed once nightly usually for 3 weeks, or until remission. Time in left lateral position: ≥30 min. Retention Time: ≥1 h, preferably all night. Hydrocortisone Aerosol / Indication is limited to Approved for adjunctive Foam2 proctitis (unlike budesonide therapy in the topical foam). treatment of UC of the ~80 mg hydrocortisone (as distal portion of the rectum 90 mg hydrocortisone in patients who cannot acetate) per ~900 mg of retain hydrocortisone or foam. other corticosteroid Body positioning and enemas. retention time not stated. Hydrocortisone Suppository Suppositories generally Approved for adjunctive reach only the distal 5 to 8 treatment of chronic UC, cm of the rectum. 3 cryptitis. Hydrocortisone / Pramoxine 1% / 1% concentration. Not approved for rectal Aerosol / Foam4 Contains topical anesthetic. use or for UC, but seems Reusable anal applicator. to be used for UC. Body positioning and Approved for retention time not stated. inflammatory and pruritic anal dermatoses. Mesalamine Enema Suspension First-line therapy. Retention time: overnight, Approved for treatment of ~8 h active mild to moderate distal UC, procto- sigmoiditis, or proctitis. Mesalamine Suppository Suppositories generally First-line therapy. reach only the distal 5 to 8 Approved for treatment of cm of the rectum. 3 active ulcerative proctitis. Nonformulary Alternatives Other Considerations Clinical Guidance None Updated version may be found at www.pbm.va.gov or PBM INTRAnet 2 Budesonide Rectal Foam Monograph Efficacy (FDA Approved Indications) Literature Search Summary A literature search was performed on PubMed/Medline (1966 to January 2016) using the search terms budesonide, aerosol, foam, rectum and rectal. The search was limited to studies performed in humans and published in the English language. Reference lists of review articles and the manufacturer’s AMCP dossier were searched for relevant clinical trials. All randomized controlled trials published in peer-reviewed journals were included. Study results were also obtained from the FDA Medical Review(s). Review of Efficacy The FDA approval of budesonide rectal foam was based on two identically-designed, multicenter, placebo- controlled, Phase 3 randomized clinical trials (RCTs) in the US and Russia that involved adults with active, mild to moderate ulcerative proctitis (limited to the rectum up to approximately 15 cm) or ulcerative proctosigmoiditis (limited to the rectum and sigmoid colon up to approximately 40 cm from the anal verge).5 The FDA determined that data for Dr. Falk Pharma’s budesonide (BUDENOFALK) foam, available in Europe since 2006 and which was modified in minor ways to develop Salix’s UCERIS foam, could be used to support efficacy and be included in pooled safety analyses for UCERIS foam, without studies to establish bioequivalence.6 Budesonide Foam Versus Placebo: Major Efficacy-Safety Trials In the two major efficacy-safety trials, Salix’s budesonide foam (2 mg / 25 ml) or placebo was given twice daily for 2 weeks, then once daily for 4 weeks. Patients were allowed to use stable doses of oral 5-ASAs up to 4.8 g per day. The combined population consisted mainly of middle-aged (mean age across pooled treatment groups, 42–44 years), white (90.1%) females (56.4%) with established proctosigmoiditis (67%) of moderate activity (89.9%) who were treated concomitantly with 5-ASAs (55.1%). The primary efficacy outcome was achievement of remission at Week 6. Remission was defined as an endoscopy score ≤1 (inactive or mild disease), rectal bleeding score of 0, and improvement or no change from baseline in the stool frequency subscore of the Modified Mayo Disease Activity Index (MMDAI). The results of the intent-to-treat (ITT) population analyses were consistent between the two trials and showed that budesonide foam had a small, statistically significant benefit over placebo in inducing remission and resolving rectal bleeding, and produced improvement in rectal bleeding as early as Week 1 (Table 1). Table 1 Pooled Results in Two 6-Week Placebo-controlled Phase 3 Trials Measure BUDF Placebo Diff NNT N = 267 N = 279 Achieved Remission, % 41.2 24.0 17.2* 6 MMDAI Rectal Bleeding Subscore of 0 at EOT, % 48.3 28.3 20.0* 5 MMDAI Rectal Bleeding Subscore of 0 at Wk 1, % 16.5 6.8 9.7* 11 Endoscopy Subscore of 0 or 1 at EOT, % 55.8 39.8 16.0* 7 * P ≤ 0.0005. EOT, End of Treatment / Week 6; BUDF, Budesonide foam; MMDAI, Modified Mayo Disease Activity Index. Both RCTs showed no significant treatment differences in terms of the percentage of patients with improved or no change in the MMDAI stool frequency subscore. (However, stool frequency may not be a robust outcome measure for rectal therapy in ulcerative proctitis.7) Budesonide rectal foam was significantly better than placebo in terms of remission, rectal bleeding subscore of 0, and endoscopy subscore of 0 or 1 in almost all subgroups (i.e., age, sex, white race, mild or moderate disease activity, established disease, smoking history, extent of disease, baseline use of mesalamine, and country).5 No statistically significant difference was seen for the endoscopy subscore of 0 or 1 in the proctitis subgroup. No statistically
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • Advice for Patients Who Take Replacement Steroids (Hydrocortisone, Prednisolone, Dexamethasone Or Plenadren) for Pituitary/Adrenal Insufficiency
    Advice for patients who take replacement steroids (hydrocortisone, prednisolone, dexamethasone or plenadren) for pituitary/adrenal insufficiency A number of you have been in touch looking for advice relating to the global coronavirus (also known as COVID-19) outbreak. If you are on steroid replacement therapy for pituitary or adrenal disease, or care for someone who is, and you’re worried about coronavirus, we’ve brought together a number of resources that we hope you will find useful. Coronavirus Adrenal Insufficiency Advice for Patients Primary adrenal insufficiency refers to all patients with loss of function of the adrenal itself, mostly either due to autoimmune Addison’s disease, or other causes such as congenital adrenal hyperplasia, bilateral adrenalectomy and adrenoleukodystrophy. The overwhelming majority of primary adrenal insufficiency patients suffer from both glucocorticoid and mineralocorticoid deficiency and usually take hydrocortisone (or prednisolone) and fludrocortisone. Our guidance similarly applies to patients with secondary adrenal insufficiency mostly due to pituitary tumours or previous high-dose glucocorticoid treatment. These patients take hydrocortisone for glucocorticoid deficiency As you will be aware it is important for patients with adrenal insufficiency to increase their steroids if unwell as per the usual sick day rules. Please ensure you have sufficient supplies to cover increased doses if you become unwell and an up to date emergency injection of hydrocortisone 100mg. Patients who suffer from a suspected or confirmed infection with coronavirus usually have high fever for many hours of the day, which results in the need for larger than usual steroid doses, so we advise slightly different sick day rules, which are listed below.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • Differential Effects of Hydrocortisone, Prednisone, And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Nebesio et al. International Journal of Pediatric Endocrinology (2016) 2016:17 DOI 10.1186/s13633-016-0035-5 RESEARCH Open Access Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia Todd D. Nebesio1*, Jamie L. Renbarger2,3, Zeina M. Nabhan1, Sydney E. Ross2, James E. Slaven4, Lang Li5, Emily C. Walvoord1 and Erica A. Eugster1 Abstract Background: Little is known about the comparative effects of different glucocorticoids on the adrenal and growth hormone (GH) axes in children with congenital adrenal hyperplasia (CAH). We sought to compare the effects of hydrocortisone (HC), prednisone (PDN), and dexamethasone (DEX) in children with classic CAH and to investigate a potential role of pharmacogenetics. Methods: Subjects were randomly assigned to three sequential 6-week courses of HC, PDN, and DEX, each followed by evaluation of adrenal hormones, IGF-1, GH, and body mass index (BMI). Single nucleotide polymorphism (SNP) analysis of genes in the glucocorticoid pathway was also performed. Results: Nine prepubertal subjects aged 8.1 ± 2.3 years completed the study. Mean ACTH, androstenedione, and 17-hydroxyprogesterone (17-OHP) values were lower following the DEX arm of the study than after subjects received HC (p ≤ 0.016) or PDN (p ≤ 0.002). 17-OHP was also lower after HC than PDN (p < 0.001). There was no difference in IGF-1, GH, or change in BMI. SNP analysis revealed significant associations between hormone concentrations, pharmacokinetic parameters, and variants in several glucocorticoid pathway genes (ABCB1, NR3C1, IP013, GLCCI1).
    [Show full text]
  • Medrol® Methylprednisolone Tablets, USP
    Medrol® methylprednisolone tablets, USP DESCRIPTION MEDROL Tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21­ trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. The structural formula is represented below: Each MEDROL Tablet for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. Inactive ingredients: 2 mg 4 mg and 8 mg Calcium Stearate Calcium Stearate Corn Starch Corn Starch Erythrosine Sodium Lactose Lactose Sucrose Mineral Oil Sorbic Acid Sucrose 16 mg and 32 mg Calcium Stearate Corn Starch Lactose Mineral Oil Sucrose 1 Reference ID: 4296332 ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli. INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
    [Show full text]
  • Hydrocortisone Vs. Dexamethasone Treatment for Bronchopulmonary Dysplasia and Their Effects on General Movements in Preterm Infants
    nature publishing group Articles Clinical Investigation Hydrocortisone vs. dexamethasone treatment for bronchopulmonary dysplasia and their effects on general movements in preterm infants Marrit M. Hitzert1, Manon J.N.L. Benders2, Annemiek M. Roescher1, Frank van Bel2, Linda S. de Vries2 and Arend F. Bos1 INTRODUCTION: Hydrocortisone (HC) and dexamethasone neurological outcome as compared to controls (6,7). A two- (DXM) are used to treat preterm infants at risk for bronchopul- center comparative study reported that HC-treated children monary dysplasia (BPD). This may, however, affect their long- had a better cognitive and motor neurodevelopmental outcome term neurological development. We aimed to determine the as compared to DXM-treated children (8). In a recent system- effect of HC and DXM therapy in preterm infants on neurologi- atic review, however, early postnatal HC therapy showed no cal functioning as assessed by the quality of general movements improvement in mortality, the rates of BPD, or in-home oxygen (GMs) until 3 months after term. dependence (9). As yet, no consensus exists regarding the most RESULTS: We found no difference in the quality of GMs between optimal therapy for preterm infants at risk for BPD. HC and DXM infants until term age. At 3 months, HC infants had The qualitative assessment of general movements (GMs) a higher median motor optimality score (MOS) than DXM infants from video recordings is a sensitive, noninvasive method to (25 vs. 21, P = 0.015). In the DXM group, MOS on the first day of investigate the integrity of the young infant’s brain (10,11). This treatment was lower than before treatment (10 vs.
    [Show full text]
  • Rectal Corticosteroids Versus Alternative Treatments in Ulcerative Colitis: a Meta-Analysis Gut: First Published As 10.1136/Gut.40.6.775 on 1 June 1997
    Gut 1997; 40: 775-781 775 Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut: first published as 10.1136/gut.40.6.775 on 1 June 1997. Downloaded from J K Marshall, E J Irvine Abstract medication consistently to the splenic Background-Clear strategies to optimise flexure,49 and a larger volume seems to allow the use of corticosteroids in ulcerative more proximal delivery.10 11 Rectal foam dis- colitis are lacking. seminates medication to the rectum and distal Aim-A meta-analysis was undertaken to descending colon,'2-16 whereas suppositories examine critically the role of rectal corti- coat only the rectum.'7 18 costeroids in the management of active Although studies of rectally administered distal ulcerative colitis. corticosteroids have reported fewer systemic Methods-AJl reported randomised con- adverse effects than with oral preparations, trolled trials were retrieved by searching plasma concentrations of prednisolone were the Medline and EMBASE databases and similar after administration of identical oral or the bibliographies of relevant studies. rectal doses.'9 20 Suppression of the hypo- Trials which met inclusion criteria were thalamic-pituitary-adrenal axis in association assessed for scientific rigour. Data were with rectal therapy has also been shown.2' 26 extracted by two independent observers Newer topically active corticosteroids such according to predetermined criteria. as tixocortol, beclomethasone, prednisolone Results-Of 83 trials retrieved, 33 met metasulphabenzoate, and budesonide, with inclusion criteria. Pooled odds ratios restricted absorption or rapid hepatic metab- (POR) showed conventional rectal corti- olism have been developed to reduce the costeroids and rectal budesonide to be adverse effects associated with conventional clearly superior to placebo.
    [Show full text]